[177Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models

被引:10
|
作者
Zeng, Ziqing [1 ]
Li, Liqiang [1 ]
Tao, Jinping [1 ]
Liu, Jiayue [1 ]
Li, Hongjun [2 ]
Qian, Xueming [2 ]
Yang, Zhi [1 ]
Zhu, Hua [1 ]
机构
[1] Peking Univ Canc Hosp & Inst, NMPA Key Lab Res & Evaluat Radiopharmaceut, State Key Lab Holist Integrat Management Gastroint, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
[2] Suzhou Transcenta Therapeut Co Ltd, Suzhou 215127, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
CLDN18.2; Lu-177; Tumor radioimmunotherapy; Radionuclide therapy; Gastric cancer; PRETARGETED RADIOIMMUNOTHERAPY; CLAUDIN-18; EXPRESSION; GENE;
D O I
10.1007/s00259-023-06561-1
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: Gastric cancer (GC), one of the most prevalent and deadliest tumors worldwide, is often diagnosed at an advanced stage with limited treatment options and poor prognosis. The development of a CLDN18.2-targeted radioimmunotherapy probe is a potential treatment option for GC.Methods: The CLDN18.2 antibody TST001 (provided by Transcenta) was conjugated with DOTA and radiolabeled with the radioactive nuclide Lu-177. The specificity and targeting ability were evaluated by cell uptake, imaging and biodistribution experiments. In BGC823(CLDN18.2)/AGS(CLDN18.2) mouse models, the efficacy of [Lu-177]Lu-TST001 against CLDN18.2-expressing tumors was demonstrated, and toxicity was evaluated by H&E staining and blood sample testing.Results: [Lu-177]Lu-TST001 was labeled with an 99.17%+/- 0.32 radiochemical purity, an 18.50 +/- 1.27 MBq/nmol specific activity and a stability of >= 94% after 7 days. It exhibited specific and high tumor uptake in CLDN18.2-positive xenografts of GC mouse models. Survival studies in BGC823(CLDN18.2) and AGS(CLDN18.2) tumor-bearing mouse models indicated that a low dose of 5.55 MBq and a high dose of 11.10 MBq [Lu-177]Lu-TST001 significantly inhibited tumor growth compared to the saline control group, with the 11.1 MBq group showing better therapeutic efficacy. Histological staining with hematoxylin and eosin (H&E) and Ki67 immunohistochemistry of residual tissues confirmed tumor tissue destruction and reduced tumor cell proliferation following treatment. H&E showed that there was no significant short-term toxicity observed in the heart, spleen, stomach or other important organs when treated with a high dose of [Lu-177]Lu-TST001, and no apparent hematotoxicity or liver toxicity was observed.Conclusion: In preclinical studies, [Lu-177]Lu-TST001 demonstrated significant antitumor efficacy with acceptable toxicity. It exhibits strong potential for clinical translation, providing a new promising treatment option for CLDN18.2-overexpressing tumors, including GC.
引用
收藏
页码:1221 / 1232
页数:12
相关论文
共 50 条
  • [1] [177Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models
    Ziqing Zeng
    Liqiang Li
    Jinping Tao
    Jiayue Liu
    Hongjun Li
    Xueming Qian
    Zhi Yang
    Hua Zhu
    European Journal of Nuclear Medicine and Molecular Imaging, 2024, 51 : 1221 - 1232
  • [2] Development and Characterization of the [177Lu]Lu-Labeled Anti-CDH17 Nanobody Derivative for Radioimmunotherapy in the Gastric Cancer Xenograft Model
    Mao, Chenkai
    Li, Shicheng
    Fan, Rencai
    Zhang, Jiaqi
    Fan, Xinying
    Shentu, Zhen
    Zhuang, Zhixiang
    Gan, Lei
    MOLECULAR PHARMACEUTICS, 2025, 22 (04) : 2077 - 2087
  • [3] Therapeutic application of 177Lu-labeled anti-claudin-18.2 humanized VHH-based recombinant antibody in gastric cancer mouse xenograft model
    Wei, Z.
    Li, B.
    Li, C.
    Chen, X.
    Zhang, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S826 - S826
  • [4] 177Lu-DZ-1demonstrated radioimmunotherapy potential in lung cancer mouse xenograft models
    Huang, MingXing
    Wang, Rang
    Wang, Weichen
    Tian, Rong
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [5] Preclinical Evaluation of [18F]ML-10 to Assessment of Radioimmunotherapy with [177Lu]Lu-Labeled Antibody
    Lee, S.
    Ko, N.
    Cho, E.
    Chung, J.
    Kim, S.
    Lim, S.
    Oh, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S673 - S673
  • [6] RADIOIMMUNOTHERAPY OF BREAST CANCER WITH 177LU LABELED MONOCLONAL ANTIBODY PR81
    Salouti, M.
    Rajabi, H.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S245 - S246
  • [7] 177Lu Anti-Angiogenic Radioimmunotherapy Targeting ATP Synthase in Gastric Cancer Model
    Park, Bok-Nam
    An, Young-Sil
    Kim, Su-Min
    Lee, Su-Jin
    Park, Yong-Jin
    Yoon, Joon-Kee
    ANTIBODIES, 2024, 13 (03)
  • [8] Radioimmunotherapy of prostate cancer with a bispecific antibody and a 177Lu-labeled peptide in a nude mouse model
    van Rij, C. M.
    Frielink, C.
    Sharkey, R. M.
    McBride, W. J.
    Rossi, E. A.
    Chang, C. -H.
    Oyen, W. J.
    Goldenberg, D. M.
    Boerman, O. C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S157 - S157
  • [9] Radiolabeling of monoclonal anti-CD105 with 177Lu for potential use in radioimmunotherapy
    Lee, So-Young
    Hong, Young-Don
    Felipe, Penelope M.
    Pyun, Mi-Sun
    Choi, Sun-Ju
    APPLIED RADIATION AND ISOTOPES, 2009, 67 (7-8) : 1366 - 1369
  • [10] Radiolabeling of Monoclonal Anti-CD105(Endoglin) with 177Lu for Potential Use in Radioimmunotherapy
    Lee, S.
    Hong, Y.
    Choi, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S319 - S320